Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys-Reference-Cited by-同舟云学术

Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys

Published:2018-06 Issue:6 Volume:26 Page:1457-1470
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Zhang Yiting,Sun Jianhua,Tan Minjia,Liu Yongzhen,Li Qian,Jiang Hua,Wang Huamao,Li Zonghai,Wan Wei,Jiang Hualiang,Lu Henglei,Wang Bingshun,Ren Jin,Gong Likun

Funder

National New Drug Creation Program of China

Independent Deployment Program

Institute of Pharmaceutical Innovation

Chinese Academy of Sciences

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference49 articles.

1. Back to the future: recombinant polyclonal antibody therapeutics;Wang;Curr. Opin. Chem. Eng.,2013

2. Therapeutic antibodies: market considerations, disease targets and bioprocessing;Elvin;Int. J. Pharm.,2013

3. EGF mutant receptor vIII as a molecular target in cancer therapy;Kuan;Endocr. Relat. Cancer,2001

4. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo;Xu;Oncotarget,2016

5. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III;Jiang;J. Biol. Chem.,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application;International Journal of Biological Macromolecules;2021-07

2. CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity;2021-04-11

3. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns;mAbs;2021-01-01

4. New Therapeutic Options for Advanced Hepatocellular Carcinoma;Cancer Control;2020-07-01